For years, the quantified self movement has left a critical gap in its dashboard. While wearables track steps, heart rate, and sleep with clinical precision, the data around menstrual cycles has remained stubbornly subjective, reliant on user-logged symptoms and estimates. Jenny Button noticed this during the COVID-19 lockdown, while wearing both an Oura ring and a Whoop band. The insight that a fundamental aspect of health for half the population was being measured with a calendar and a guess became the founding premise for Emm [TechCrunch, November 2025].
Now, after five years of development and a $9 million seed round, the Bristol-based startup is preparing to launch what it calls the world's first smart menstrual cup. It is a hardware bet in a software-saturated health tracking space, embedding ultra-thin biosensors into a reusable, medical-grade silicone cup to measure flow volume, cycle length, and regularity in real time [SeedCue, November 2025]. The data syncs to a companion app, promising to turn a routine product of menstrual care into a diagnostic-grade biosensor.
The Hardware Wedge Into Femtech
Emm's fundamental bet is that subjective logging is insufficient. Existing cycle-tracking apps are powerful tools for pattern recognition, but they depend on users accurately recalling and entering symptoms. The smart cup is designed to collect objective, passive data on the volume and timing of menstrual flow. The company claims its sensors can establish a personal baseline within three cycles, enabling the app to highlight deviations that could signal underlying conditions like endometriosis, PCOS, or menorrhagia [SeedCue, November 2025].
A Seed Round Built on Wearables Credibility
The $9 million seed round, closed in November 2025 and led by Lunar Ventures, signals strong investor belief in this hardware approach. Key investors include Labcorp Venture Fund, Harpreet Rai (former CEO of Oura), Vivek Garipalli (founder of Clover Health), and Amar Shah (co-founder of Wayve) [TechCrunch, November 2025].
The Team and the Long Road to Launch
Button has built a team that reflects the product's hybrid nature, including a Chief Design Officer, a VP of Product, a Clinical Research and Partnerships Manager, and a Senior Electronics Engineer [emm.co]. Button spent five years iterating through thousands of designs before arriving at the current product [SeedCue, November 2025]. The company is currently in a pre-launch phase, with a UK rollout targeted for early 2026, followed by a US entry in 2027 [TechCrunch, November 2025].
Navigating the Inevitable Headwinds
Emm's path is lined with challenges, including regulatory classification as a medical device, the need for clinical validation through peer-reviewed studies, and the requirement for impeccable data privacy governance. Its success hinges on proving the value of the data is worth the change in behavior and cost for the consumer.
The Patient Population and Standard of Care
The ultimate test for Emm will be its impact on the lived experience of menstrual health. If Emm's cup can provide reliable, longitudinal data that a person can bring to their clinician, it could shift the paradigm toward earlier intervention and more data-informed conversations.